Market Overview

5 Stocks Cut In Half In 2016

5 Stocks Cut In Half In 2016
Related VRX
Donald Trump Has Become To Aerospace What Hillary Clinton Was To Pharma
Trump: Drug Industry Is 'Getting Away With Murder'
A Fond Farewell (GuruFocus)
Related FIT
Watch These 7 Huge Call Purchases In Tuesday Trade
10 Stocks That Have Short Sellers' Attention So Far In 2017
My Top 3 Picks For 2017 (Seeking Alpha)

After a disastrous start to the year, the S&P 500 has bounced back strongly. Now that the first half of 2016 has come and gone, the January sell-off is a distant memory for most investors, and the SPDR S&P 500 ETF Trust (NYSE: SPY) is up a solid 2.1 percent year-to-date.

Unfortunately, not every stock got an invitation to the party. Here’s a look at five stocks that have lost more than half their value so far in 2016.

1. Ionis Pharmaceuticals Inc (NASDAQ: IONS)

Ionis shares plunged 35 percent in a single morning in May after GlaxoSmithKline plc (ADR) (NYSE: GSK) declined to initiate a Phase III study of the IONIS-TTR drug program. Ionis’ stock is now down 51.3 percent on the year.

2. SolarCity Corp (NASDAQ: SCTY)

Not even a buyout bid by Tesla Motors Inc (NASDAQ: TSLA) could salvage a disastrous first half of 2016 for SolarCity. After a lackluster 0.7 percent decline in 2015, the stock is down 53.5 percent in 2016.

Related Link: Just How 'Safe' Are U.S. Stocks Post-Brexit?

3. Fitbit Inc (NYSE: FIT)

Fitbit continues to struggle to differentiate its products in an increasingly competitive wearable devices market. So far this year, the stock has fallen 57.8 percent.

4. Endo International plc – Ordinary Shares (NASDAQ: ENDP)

Endo’s stock tanked more than 25 percent following the company’s severe outlook cut in May. Year-to-date, Endo is now down 72.2 percent.

5. Valeant Pharmaceuticals Intl Inc (NYSE: VRX)

Valeant’s struggles with accusations of accounting scandal, price gouging and a questionable business model have been highly-publicized. It seems as though very few investors outside of Bill Ackman are willing to bet on a Valeant recovery. The stock is down 79.8 percent in 2016.

Disclosure: The author holds no position in the stocks mentioned.

Posted-In: Bill AckmanBiotech Education Health Care Top Stories Movers Trading Ideas General Best of Benzinga


Related Articles (FIT + ENDP)

View Comments and Join the Discussion!